Regeneron Pharmaceuticals
REGN5668
Ovarian Cancer
Countdown
261days
Phase 2 readout · Mar 25, 2027
What's at stake
Phase 2 trial results for REGN5668 in Ovarian Cancer are due Mar 25, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT04590326: Phase 2 trial, sponsor Regeneron Pharmaceuticals, drug REGN5668. Primary completion date 2027-03-25 (estimated).”